Ireland
--:--IST
Recruiting Not applicable

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

NCT06649240 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2024-10-04
Last updated
2026-09-11

Condition(s) studied

Ischemic StrokeSmall Vessel Cerebrovascular DiseaseCholesterol, LDLSecondary PreventionCardiovascular Diseases

Investigational drug(s) / intervention(s)

Statins and/or Ezetimibe →PCSK9 inhibitor →

Statins and/or Ezetimibe: Statin ± Ezetimibe to achieve target LDL-cholesterol level

PCSK9 inhibitor: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.

Study summary

Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, baseline LDL-cholesterol \<70 mg/dL in the absence of lipid-lowering therapy, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \<70 mg/dL (intensive group) or 90-110 mg/dL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 19 years or older 2. Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI or CT) 3. Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment 4. Patients or guardians who agree to the study protocol and sign with informed consent Exclusion Criteria: 1. Extracranial or intracranial large artery stenosis ≥50% 2. History of atherosclerotic ischemic stroke or transient ischemic attack 3. Documented coronary artery disease 4. Documented peripheral artery disease or aortic atherosclerotic disease 5. Diabetes with one or more of the following: duration ≥10 years; ≥2 major risk factors (men ≥45 years, women ≥55 years; family history of premature atherosclerotic cardiovascular disease; hypertension; current smoking; or HDL cholesterol \<40 mg/dL); or known evidence of target organ damage (albuminuria, estimated glomerular filtration rate \<60 mL/min per 1.73 m², retinopathy, neuropathy, or left ventricular hypertrophy) 6. Baseline LDL cholesterol \<70 mg/dL in the absence of lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors, etc.) 7. Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit, muscle disorders, hypersensitivity to statins, or taking medications contraindicated for use with statins) 8. Women who are pregnant, breastfeeding, or intending to become pregnant during the study period 9. Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion

Primary outcome measure(s)

  • Major adverse cardiovascular event — 4 years
    Major adverse cardiovascular event (MACE) includes cardiovascular death, stroke, and acute coronoary syndrome (i.e., ST-elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina).

Trial sites (46)

FacilityCityRegionStatus
Korea University Ansan Hospital Ansan South Korea Recruiting
Hallym University Sacred Heart Hospital Anyang South Korea Recruiting
Pusan National University Hospital Busan South Korea Recruiting
Gyeongsang National University Changwon Hospital Changwon South Korea Recruiting
Samsung Changwon Hospital Changwon South Korea Recruiting
Chungbuk National University Hospital Cheongju-si South Korea Recruiting
Hallym University Chuncheon Sacred Heart Hospital Chuncheon South Korea Recruiting
Kangwon National University Hospital Chuncheon South Korea Recruiting
Daegu Catholic University Medical Center Daegu South Korea Recruiting
Keimyung University Dongsan Medical Center Daegu South Korea Recruiting
Kyungpook National University Chilgok Hospital Daegu South Korea Recruiting
Kyungpook National University Hospital Daegu South Korea Recruiting
Chungnam National University Hospital Daejeon South Korea Recruiting
Daejeon Eulji Medical Center Daejeon South Korea Recruiting
Dongguk University Ilsan Hospital Goyang South Korea Withdrawn
Ilsan Paik Hospital Goyang South Korea Recruiting
National Health Insurance Service Ilsan Hospital Goyang South Korea Recruiting
Hanyang University Guri Hospital Guri-si South Korea Recruiting
Chonnam National University Hospital Gwangju South Korea Recruiting
Chosun University Hospital Gwangju South Korea Withdrawn
Chung-Ang University Gwangmyeong Hospital Gwangmyeong South Korea Recruiting
Dongtan Sacred Heart Hospital Hwaseong South Korea Recruiting
Wonkwang University Hospital Iksan South Korea Recruiting
Gachon University Gil Medical Center Incheon South Korea Recruiting
Inha University Hospital Incheon South Korea Recruiting
International St. Mary's Hospital Incheon South Korea Withdrawn
Jeju National University Hospital Jeju City South Korea Recruiting
Seoul National University Bundang Hospital Seongnam South Korea Recruiting
Asan Medical Center Seoul South Korea Recruiting
Chung-Ang University Hospital Seoul South Korea Recruiting
Ewha Womans University Mokdong Hospital Seoul South Korea Recruiting
Ewha Womans University Seoul Hospital Seoul South Korea Recruiting
Gangnam Severance Hospital Seoul South Korea Recruiting
Hallym University Kangdong Sacred Heart Hospital Seoul South Korea Recruiting
Hanyang University Seoul Hospital Seoul South Korea Recruiting
Konkuk University Medical Center Seoul South Korea Recruiting
Korea University Anam Hospital Seoul South Korea Recruiting
Kyung Hee University Medical Center Seoul South Korea Recruiting
National Medical Center Seoul South Korea Recruiting
Nowon Eulji Medical Center Seoul South Korea Recruiting

+ 6 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06649240 on ClinicalTrials.gov ↗ ← All trials in South Korea